Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysmethynil SCHEMBL29711661 | 1.00 | ICMT (1.00) | ICMT | |
| SCHEMBL11949503 | 0.92 | ICMT (0.85) | ICMT | |
| SCHEMBL11949506 | 0.91 | ICMT (0.83) | ICMT | |
| SCHEMBL9237545 | 0.90 | ICMT (1.00) | ICMT | |
| SCHEMBL9234492 | 0.90 | ICMT (1.00) | ICMT | |
| SCHEMBL9232620 | 0.90 | ICMT (1.00) | ICMT | |
| SCHEMBL9233646 | 0.89 | ICMT (0.80) | ICMT | |
| SCHEMBL12572747 | 0.89 | ICMT (1.00) | ICMT | |
| SCHEMBL9233660 | 0.88 | ICMT (1.00) | ICMT | |
| SCHEMBL9235215 | 0.88 | ICMT (0.85) | ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-9422238-B2 | ICMT inhibitors | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9422238-B2 | ICMT inhibitors | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9422238-B2 | ICMT inhibitors | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-20150218095-A1 | ICMT INHIBITORS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2015-08-06 | — | — | US | disclosed |
| US-20150218095-A1 | ICMT INHIBITORS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2015-08-06 | — | — | US | disclosed |
| US-20150218095-A1 | ICMT INHIBITORS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2015-08-06 | — | — | US | disclosed |
| US-20150182452-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | ONCOSYNERGY INC (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150182452-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | ONCOSYNERGY INC (US) | 2015-07-02 | — | — | US | disclosed |
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| US-7964629-B2 | 2-[5-(3-Methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethynil) and derivatives; anticarcinogenic agents; leukemia; antiinflammatory agents; multiple sclerosis, antiarthritic agents; rheumatic diseases;osteoporosis, stroke, asthma; glaucoma; screening; catalyzed CaaX protein methylation | Duke Universtiy (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964629-B2 | 2-[5-(3-Methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethynil) and derivatives; anticarcinogenic agents; leukemia; antiinflammatory agents; multiple sclerosis, antiarthritic agents; rheumatic diseases;osteoporosis, stroke, asthma; glaucoma; screening; catalyzed CaaX protein methylation | Duke Universtiy (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090118240-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118240-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2009-05-07 | — | — | US | disclosed |
| EP-1956910-A2 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | The Board of Regents of The University of Texas System (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171782-A1 | Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-07-17 | — | — | US | disclosed |
| US-20080171782-A1 | Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-07-17 | — | — | US | disclosed |
| WO-2007062399-A2 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006102126-A2 | INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE | DUKE UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171782-A1 | Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | BHMT, ICMT, TPMT | ICMT 2/4885 |
| US-20150218095-A1 | ICMT INHIBITORS | INMT, CEPT1, ICMT | ICMT 3/4885 |
| US-20090118240-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | VHL, NGF, S100B | ICMT 3249/4885 |
| US-20150182452-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | VHL, NGF, S100B | ICMT 3249/4885 |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ICMT 1391/4885 |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | ABCC1, TSG101, BRCA1 | ICMT 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.